Biotechnology / Medical Research

Page 1

Taiwan Liposome Co Ltd to invest in sub-subsidiary

Friday, 20 Jun 2014 06:44am EDT

Taiwan Liposome Co Ltd:To invest 500,000 yuan to set up a new wholly owned medicine sub-subsidiary in Shanghai through TLC Biopharmaceuticals (H.K.) Limited.

Taiwan Liposome Co Ltd to set up new subsidiary

Thursday, 19 Jun 2014 06:48am EDT

Taiwan Liposome Co Ltd:To invest $100,000 to set up a new wholly owned subsidiary named TLC Biopharmaceuticals (H.K.) Limited.

3-D Matrix Ltd to establish subsidiary

Tuesday, 17 Jun 2014 02:30am EDT

3-D Matrix Ltd:To establish a 99 pct owned subsidiary named 3-D Matrix Da America Latina Representação Comercial Ltda., based in Brazil on June 13 with subsidiary 3-D Matrix Europe SAS (1 pct owned of new company).New subsidiary to be engaged in medical products business of hemostatic material, in South America.New subsidiary to be capitalized at 600,000 real, or about 27 mln yen.

Zeltia French subsidiary initiates its commercial activity

Monday, 26 May 2014 02:31am EDT

Zeltia SA:French subsidiary of PharmaMar SA initiates its commercial activity.

Taiwan Liposome Co Ltd to set up new branch

Thursday, 8 May 2014 05:51am EDT

Taiwan Liposome Co Ltd:To set up Xinzhu branch.

Vermillion Inc launches ASPiRA Labs

Monday, 28 Apr 2014 07:00am EDT

Vermillion Inc:Launches ASPiRA Labs, which will specialize in applying the latest biomarker-based technologies to address critical needs in the management of gynecologic cancers.Initially, the lab will process diagnostic tests and clinical decision aids for women's health in ovarian cancer, and then will expand to other gynecologic conditions with high unmet need.

Diamyd Medical AB signs agreement with group of founding partners and Karolinska Institutet Holding AB to invest in cord blood bank in Sweden

Thursday, 3 Apr 2014 02:30am EDT

Diamyd Medical AB:Says it has signed agreement with group of founding partners and Karolinska Institutet Holding AB, by which it agrees to invest 11.5 mln Swedish crowns for establishment of commercial cord blood bank in Sweden for private family saving of umbilical cord blood and other sources of stem cells.Intention is also to collect and make available stem cells from umbilical cord tissue for research purposes in order to advance the fields of stem cells and regenerative medicine, including research within type 1 diabetes.New company will be capitalized with 14 mln crowns in total.Diamyd Medical will receive preference shares corresponding to 46 pct of the new company and have board representation.Head of the new venture will be Hans-Peter Ekre, one of the founding partners, with prior experience as R&D director and entrepreneur from KabiPharmacia, Astra and Karolinska Development.

Hybrigenics launches Helixio, its new branch dedicated to genomic services

Thursday, 3 Apr 2014 02:00am EDT

Hybrigenics SA:Launches Helixio, its new branch dedicated to genomic services.With acquisition of genomic division of Imaxio in 2013, Hybrigenics has gained access to technologies based on DNA or RNA microarrays (“chips”) and on sequencing.Hybrigenics wants to expand this activity by marketing it under new name of Helixio.

Senesco Technologies opens two new clinical trial sites and initiates treatment of patient in South Africa

Wednesday, 12 Mar 2014 08:15am EDT

Senesco Technologies Inc:Opening of two new sites in Republic of South Africa at Pretoria East Hospital and Groote Schuur Hospital in Cape Town.Treatment of first patient in South Africa has been initiated in Senesco's Phase 1b/2a clinical study of its product candidate, SNS01-T.

Institut stvolovykh kletok cheloveka OAO and Hemafund open biotech center in Kyiv-Interfax

Monday, 24 Feb 2014 05:32am EST

Institut stvolovykh kletok cheloveka OAO:LLC Hemafund Medical Center in Ukraine has opened a biotech complex in Kyiv, the company said in a press release-Interfax.Russian biotech company Human Stem Cells Institute (HSCI) owns 50 percent of Hemafund.The new center will cover an area of 1,000 square meters.How much was invested in the project was not disclosed.The center includes a cryo-reservoir, research lab, facilities for the development and freezing of umbilical cord blood and other tissues, as well as a customer department and logistics service.Hemafund is a Ukrainian cord blood bank.HSCI acquired 50 percent of Hemafund in 2010 for $1.5 million.British company Melton Consortium Ltd owns the other 50 percent.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.